Replimune Securities Class Action Over FDA Rejection
Analysis based on 6 articles · First reported Sep 03, 2026 · Last updated Sep 22, 2026
The lawsuit adds legal and reputational pressure on Replimune Group after the United States — Food and Drug Administration rejection already wiped out most of its market value, keeping downside risk elevated for the stock. Broader biotech sentiment may see modest caution as single-arm trial designs and accelerated approval pathways face heightened scrutiny from regulators and litigators.
Pomerantz LLP announced a securities class action lawsuit against Replimune Group on behalf of investors who acquired Replimune securities during the Class Period. The suit alleges that Replimune and certain officers and/or directors engaged in securities fraud or other unlawful business practices. The underlying dispute stems from the United States — Food and Drug Administration's April 10, 2026 Complete Response Letter rejecting Replimune's Biologics License Application for RP1 in combination with Nivolumab. The United States — Food and Drug Administration cited deficiencies in the RPL-001-16 (IGNYTE) and RP1-104 (IGNYTE-3) studies, stating the evidence did not meet evidentiary standards for regulatory approval and that the RPL-001-16 trial was not an adequate and well-controlled investigation demonstrating substantial evidence of effectiveness. The agency also noted that Replimune had submitted objective response rate data from an early unplanned analysis of only 40 patients, 10 percent of the planned 400-patient enrollment, and that previously communicated study design concerns were not addressed. Following the news, Replimune shares fell 1.15 dollars, or 19.46 percent, to close at 4.76 dollars on April 10, 2026, and continued falling 3.06 dollars, or 64.29 percent, to close at 1.70 dollars on April 13, 2026. Investors have until October 5, 2026 to seek appointment as Lead Plaintiff. Pomerantz LLP is soliciting affected investors to join the action.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard